Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during the pollen season and influence of probiotic intake

Journal of Investigational Allergology and Clinical Immunology

Volumn 17, Issue 2, 2007, Pages 92-100

  Odamaki, Toshitaka ^a   Xiao, J Z ^a   Iwabuchi, N ^a   Sakamoto, M ^b   Takahashi, N ^a   Kondo, S ^a   Iwatsuki, K ^a   Kokubo, S ^a   Togashi, H ^c   Enomoto, T ^d   Benno, Y ^b  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b RIKEN BIORESOURCE CENTER   (Japan)

^c Togashi Clinic   (Japan)

^d JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Allergy; Bifidobacterium longum; Cytokine; Japanese cedar pollinosis; Probiotic

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; PROBIOTIC AGENT; YOGHURT;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; BIFIDOBACTERIUM LONGUM; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FECES ANALYSIS; FEMALE; HUMAN; JAPANESE CEDAR; MALE; POLLEN ALLERGY; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; BIFIDOBACTERIUM; COLONY COUNT, MICROBIAL; CRYPTOMERIA; EOSINOPHILIA; FECES; FEMALE; HUMANS; INTERFERON TYPE II; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PROBIOTICS; RHINITIS, ALLERGIC, SEASONAL; YOGURT;

EID: 34247197568     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Warner JO. Worldwide variations in the prevalence of atopic symptoms: what does it all mean? Thorax. 1999;54: S46-51.
2. Holt PG, Sly PD, Bjorksten B. Atopic versus infectious diseases in childhood: a question of balance? Pediatr Allergy Immunol. 1997;8: 53-8.
3. Sudo N, Aiba Y, Oyama N, Yu X N, Matsunaga M, Koga Y, Kubo C. Dietary nucleic acid and intestinal microbiota synergistically promote a shift in the Th1/Th2 balance toward Th1-skewed immunity. Int Arch Allergy Immunol. 2004;135: 132-5. Epub 2004 Sep 2.
4. Oyama N, Sudo N, Sogawa H, Kubo C. Antibiotic use during infancy promote a shift in the T(H)1/T(H)2 balance toward T(H)2-dominant immunity in mice. J Allergy Clin Immunol. 2001;107: 153-9.
5. Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The Intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy. 1999;108: 342-6.
6. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108: 516-520.
7. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076-9.
8. Ishida Y, Nakamura F, Kanzato H, Sawada D, Hirata H, Nishimura A, Kajimoto O, Fujiwara S. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci. 2005;88:527-33.
9. Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol. 2004;5: 152-8.
10. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997;99:179-85.
11. Kirjavainen PV, Gibson GR. Healthy gut microflora and allergy: factors influencing development of the microbiota. Ann Med. 1999;31:288-92.
12. Enomoto, T. Reevaluation of hygiene theory. Arerugi. 2004;53:465-8. Japanese
13. Xiao JZ, Kondo S, Yanagisawa N, Takahashi N, Odamaki T, Iwabuchi N, Iwatsuki K, Kokubo S, Togashi H, Enomoto K, Enomoto T. Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season, a randomized, double-blind, placebo-controlled trial. J Invest Allergol Clin Immunol. 2006;16: 86-93.
14. Sakamoto M, Hayashi H, Benno Y. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol. Immunol. 2003;47: 133-42.
15. Hayashi H, Sakamoto M, Benno Y. Evaluation of three different forward primers by terminal restriction fragment length polymorphism analysis for determination of fecal bifidobacterium spp. in Healthy Subjects. Microbiol Immunol. 2004;48:1-6.
16. Egert M, Friedrich MW. Formation of pseudo-terminal restriction fragments, a PCR-related bias affecting terminal restriction fragment length polymorphism analysis of microbial community structure. Appl Environ Microbiol. 2003;69:2555-62.
17. Nagashima K, Hisada T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacterial populations in human feces. Appl Environ Microbiol 2003;69:1251-62.
18. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl. Environ. Microbiol. 2004;70:7220-28.
19. Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F, Caramelli E, Matteuzzi D, Campieri M. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38:165-172.
20. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Review article: bifidobacteria as probiotic agents - physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005;22:495-512.
21. He F, Ouwehand AC, Isolauri E, Hashimoto H, Benno Y, Salminen S. Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol Med Microbiol. 2001;30:43-7.
22. Yamasak, S, Tsuyuki S, Akashiba H, Kamimura H, Kimura M, Kawashima T, Ueda K. Immune response of Bifidobacterium-associated mice. Bifidobacteria Microflora. 1991;10:19-31.
23. Sekine K, Ohta J, Onishi M, Tatsuki T, Shimokawa Y, Toida T, Kawashima T, Hashimoto Y. Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. Biol Pharm Bull. 1995;18: 148-53.
24. Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3- methylimidazo[4,5-f] quinoline, a food mutagen. Cancer Res. 1993;53: 3914-8.
25. Yaeshima T, Takashashi S, Matsumoto N, Ishibashi N, Hayasawa H, Iino H. Effect of yogurt containing Bifidobacterium longum BB536 on the intestinal environment, fecal characteristics and defecation frequency: a comparison with standard yogurt. Biosci Microflora. 1997;16:73-7.
26. Namba K, Yaeshima T, Takashashi S, Ishibashi N, Hayasawa H, Yamasaki S. Inhibitory effects of Bifidobacterium longum BB536 on enterohemorrhagic Escherichia coli O157:H7. Biosci Microflora. 2003;22:85-91.
27. Kirjavainen PV, Arvola T, Salminen SJ, Isolauri E. Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 2002;51:51-5.
28. Fukuda S, Ishikawa H, Koga Y, Aiba Y, Nakashima K, Cheng L, Shirakawa T. Allergic symptoms and microflora in schoolchildren. J Adolesc Health. 2004;35:156-8.